Studi scientifici principali
- A Phase 3 Double-Blind Placebo-Controlled Evaluation of Sofosbuvir/velpatasvir Fixed-Dose Combination for 12 Weeks in Genotype 1, 2, 4, 5, 6 HCV-Infected Patients: Results of the ASTRAL-1 Study - 66th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA Nov 13-17 201
- A Randomized Controlled Trial of Sofosbuvir/velpatasvir Fixed-Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 12 Weeks in Genotype 2 HCV-Infected Patients: The Phase 3 ASTRAL-2 Study - 66th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA Nov 13-17 201
- Sofosbuvir/velpatasvir Fixed-Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV-Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study - 66th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA Nov 13-17 201
- Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis - M.P. Curry, et al.; The new England journal of medicine, DOI: 10.1056/NEJMoa1512614
- Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir and Velpatasvir (GS-5816) and HIV Antiretoviral Therapies - 66th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA Nov 13-17 201
